NEW Product Launch - Stalevo® Tablets from Orion Pharma and Max Health

Max Health and Orion Pharma are proud to announce the launch of STALEVO® (levodopa, carbidopa and entacapone) tablets in New Zealand. Stalevo is a pioneering triple therapy for Parkinson's and is fully funded from 1 February 2025.

STALEVO combines levodopa, carbidopa, and entacapone in a single tablet, providing a convenient solution for patients not stabilised on traditional levodopa/dopa decarboxylase inhibitor treatment.

Stalevo details are as follows:

Stalevo levodopa/carbidopa/entacapone OneLink Code Pharmacode

Stalevo 50/12.5/200 1260191 2696533

Stalevo 100/25/200 1260192 2696541

Stalevo 150/37.5/200 1260193 2696568

Stalevo 200/50/200 1260194 2696576

As with all other Max Health products, Stalevo Tablets can be ordered from Onelink using this contact information.

Phone: 0800-70-80-60
Fax: 0800-26-69-60
Email: customerservices@onelink.co.nz